Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FADS1 | O60427 | 5/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755612 | 0.81 | KCNN4 (0.35) | KCNN4FADS1MAOBMDM2PTGDR2 | |
| SCHEMBL5751832 | 0.81 | MDM2 (0.35) | KCNN4FADS1MAOBMDM2PTGDR2 | |
| SCHEMBL5752903 | 0.80 | KCNN4 (0.35) | KCNN4FADS1MAOBMDM2PTGDR2 | |
| SCHEMBL5751613 | 0.79 | KCNN4 (0.39) | KCNN4MAOBMDM2PTGDR2 | |
| SCHEMBL5749871 | 0.74 | GRM5 (0.35) | UBE2MDCUN1D1FFAR4MDM2CETP | |
| SCHEMBL5752580 | 0.74 | FADS1 (0.44) | FADS1MDM2MAPT | |
| SCHEMBL5752015 | 0.73 | KCNN4 (0.34) | KCNN4FADS1MAOB | |
| SCHEMBL5751187 | 0.71 | EGLN2 (0.35) | KCNN4FADS1MAOBMAPT | |
| SCHEMBL5752464 | 0.70 | KCNN4 (0.33) | KCNN4MAOB | |
| SCHEMBL5753523 | 0.70 | HCRTR1 (0.37) | CETPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | UBE2M 3130/4885DCUN1D1 3324/4885KCNN4 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.